Caris Life Sciences Inc. (CAI) stock surged 14.70% in after-hours trading following the release of its fourth-quarter financial results.

The significant price movement was driven by the company reporting quarterly earnings of $0.28 per share, which dramatically surpassed the analyst consensus estimate of a loss of $0.03 per share. Furthermore, quarterly sales reached $292.9 million, exceeding estimates by over 40% and representing substantial growth compared to the same period last year. The company also provided optimistic revenue guidance for the full year 2026, projecting it to be between $1.0 billion and $1.02 billion.

Additional positive factors from the report included strong operational cash flow, the announcement of strategic partnerships for its forthcoming Caris Detect solution, and the achievement of key operational milestones, such as surpassing one million total profiles. These results collectively signaled robust financial health and future growth prospects to investors.